Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 93.57 -5.51% -5.46
ICPT closed down 15.77 percent on Wednesday, February 20, 2019, on 7.62 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ICPT trend table...

Date Alert Name Type % Chg
Feb 20 Fell Below 200 DMA Bearish -5.51%
Feb 20 Fell Below 20 DMA Bearish -5.51%
Feb 20 Fell Below 50 DMA Bearish -5.51%
Feb 20 MACD Bearish Centerline Cross Bearish -5.51%
Feb 20 Expansion Pivot Sell Setup Bearish Swing Setup -5.51%
Feb 20 Slingshot Bullish Bullish Swing Setup -5.51%
Feb 20 Volume Surge Other -5.51%
Feb 20 Wide Range Bar Range Expansion -5.51%
Feb 20 Earnings Movers Other -5.51%
Feb 20 Multiple of Ten Bearish Other -5.51%

Older signals for ICPT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Medical Specialties Diabetes Gastroenterology Hepatology Digestive Diseases Fibrosis
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 133.74
52 Week Low 58.03
Average Volume 769,115
200-Day Moving Average 100.2053
50-Day Moving Average 108.6336
20-Day Moving Average 114.9515
10-Day Moving Average 113.116
Average True Range 7.3359
ADX 19.17
+DI 27.073
-DI 29.3004
Chandelier Exit (Long, 3 ATRs ) 109.8623
Chandelier Exit (Short, 3 ATRs ) 120.5577
Upper Bollinger Band 124.9361
Lower Bollinger Band 104.9669
Percent B (%b) -0.3
BandWidth 17.371848
MACD Line -0.1862
MACD Signal Line 1.5548
MACD Histogram -1.7411
Fundamentals Value
Market Cap 2.48 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -6.39
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 130.37
Resistance 3 (R3) 133.69 126.56 125.14
Resistance 2 (R2) 126.56 118.58 124.90 123.40
Resistance 1 (R1) 112.80 113.65 109.24 109.48 121.66
Pivot Point 105.67 105.67 103.89 104.01 105.67
Support 1 (S1) 91.91 97.69 88.35 88.59 76.40
Support 2 (S2) 84.78 92.76 83.12 74.66
Support 3 (S3) 71.02 84.78 72.92
Support 4 (S4) 67.70